ALX Oncology Holdings Inc.
ALXO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $116,373 | $141,795 | $98,400 | $60,170 |
| G&A Expenses | $26,094 | $28,483 | $29,036 | $23,385 |
| SG&A Expenses | $26,094 | $28,483 | $29,036 | $23,385 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $142,467 | $170,278 | $127,436 | $83,555 |
| Operating Income | -$142,467 | -$170,278 | -$127,436 | -$83,555 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $7,617 | $9,473 | $4,018 | $71 |
| Pre-Tax Income | -$134,850 | -$160,805 | -$123,418 | -$83,484 |
| Tax Expense | $0 | $0 | $64 | -$21 |
| Net Income | -$134,850 | -$160,805 | -$123,482 | -$83,463 |
| % Margin | – | – | – | – |
| EPS | -2.58 | -3.74 | -3.03 | -2.07 |
| % Growth | 31% | -23.4% | -46.4% | – |
| EPS Diluted | -2.58 | -3.74 | -3.03 | -2.07 |
| Weighted Avg Shares Out | 52,175 | 42,988 | 40,700 | 40,308 |
| Weighted Avg Shares Out Dil | 52,175 | 42,988 | 40,700 | 40,308 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9,366 | $10,649 | $4,278 | $0 |
| Interest Expense | $1,729 | $1,565 | $238 | $13 |
| Depreciation & Amortization | $872 | $836 | $342 | $51 |
| EBITDA | -$132,249 | -$158,404 | -$122,838 | -$83,420 |
| % Margin | – | – | – | – |